Qianhai Health Holdings Limited (0911.HK)
HKD 0.27
(0.0%)
HKD 0.27
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 17.1 Million HKD | -95.32% |
| 2022 | 333.27 Million HKD | 1512.03% |
| 2021 | 20.67 Million HKD | -46.31% |
| 2020 | 38.5 Million HKD | 75.86% |
| 2019 | 21.89 Million HKD | -36.74% |
| 2018 | 34.61 Million HKD | 0.08% |
| 2017 | 34.58 Million HKD | -46.24% |
| 2016 | 64.33 Million HKD | -65.88% |
| 2015 | 188.56 Million HKD | 204.22% |
| 2014 | 61.98 Million HKD | 153.17% |
| 2013 | 24.48 Million HKD | 511.01% |
| 2012 | 4 Million HKD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.78 Million HKD | 0.0% |
| 2024 Q1 | 3.78 Million HKD | 104.2% |
| 2023 Q3 | 12.4 Million HKD | -88.27% |
| 2023 Q1 | 3.84 Million HKD | -98.33% |
| 2023 FY | 15.58 Million HKD | -95.32% |
| 2023 Q4 | -90.21 Million HKD | -827.16% |
| 2023 Q2 | 105.79 Million HKD | 2653.62% |
| 2022 Q4 | 230.29 Million HKD | 623.47% |
| 2022 Q3 | 31.83 Million HKD | 214.2% |
| 2022 Q1 | 4.29 Million HKD | 384.53% |
| 2022 FY | 333.27 Million HKD | 1512.03% |
| 2022 Q2 | 10.13 Million HKD | 135.96% |
| 2021 Q4 | -1.5 Million HKD | -133.75% |
| 2021 FY | 20.67 Million HKD | -46.31% |
| 2021 Q1 | 7.02 Million HKD | -60.93% |
| 2021 Q2 | 33.6 Million HKD | 378.01% |
| 2021 Q3 | 4.47 Million HKD | -86.7% |
| 2020 Q1 | 6.1 Million HKD | -38.11% |
| 2020 Q2 | 10.81 Million HKD | 77.32% |
| 2020 Q3 | 14.29 Million HKD | 32.16% |
| 2020 Q4 | 17.99 Million HKD | 25.85% |
| 2020 FY | 38.5 Million HKD | 75.86% |
| 2019 Q4 | 9.85 Million HKD | 83.75% |
| 2019 Q2 | 12.03 Million HKD | 108.04% |
| 2019 Q1 | 5.78 Million HKD | 17.48% |
| 2019 FY | 21.89 Million HKD | -36.74% |
| 2019 Q3 | 5.36 Million HKD | -55.42% |
| 2018 FY | 34.61 Million HKD | 0.08% |
| 2018 Q4 | 4.92 Million HKD | 0.0% |
| 2018 Q3 | 4.92 Million HKD | 79.22% |
| 2018 Q2 | 2.74 Million HKD | 0.0% |
| 2018 Q1 | 2.74 Million HKD | -22.56% |
| 2017 Q1 | 2.27 Million HKD | -94.2% |
| 2017 FY | 34.58 Million HKD | -46.24% |
| 2017 Q2 | 2.27 Million HKD | 0.0% |
| 2017 Q4 | 3.54 Million HKD | 0.0% |
| 2017 Q3 | 3.54 Million HKD | 55.98% |
| 2016 Q4 | 39.24 Million HKD | 0.0% |
| 2016 Q3 | 39.24 Million HKD | -7.14% |
| 2016 Q2 | 42.26 Million HKD | 0.0% |
| 2016 Q1 | 42.26 Million HKD | -68.11% |
| 2016 FY | 64.33 Million HKD | -65.88% |
| 2015 Q2 | 5.31 Million HKD | 0.0% |
| 2015 Q3 | 132.52 Million HKD | 2393.2% |
| 2015 FY | 188.56 Million HKD | 204.22% |
| 2015 Q1 | 5.31 Million HKD | -49.62% |
| 2015 Q4 | 132.52 Million HKD | 0.0% |
| 2014 Q3 | 10.55 Million HKD | -53.51% |
| 2014 Q1 | 22.69 Million HKD | 332.89% |
| 2014 FY | 61.98 Million HKD | 153.17% |
| 2014 Q4 | 10.55 Million HKD | 0.0% |
| 2014 Q2 | 22.69 Million HKD | 0.0% |
| 2013 Q2 | 2.5 Million HKD | 0.0% |
| 2013 Q4 | 5.24 Million HKD | 0.0% |
| 2013 Q3 | 5.24 Million HKD | 109.47% |
| 2013 Q1 | 2.5 Million HKD | -59.11% |
| 2013 FY | 24.48 Million HKD | 511.01% |
| 2012 FY | 4 Million HKD | 0.0% |
| 2012 Q4 | 6.12 Million HKD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | 29.979% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 99.557% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | 51.862% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | 95.168% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | 97.106% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 98.608% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | 96.603% |
| PuraPharm Corporation Limited | 216.62 Million HKD | 92.105% |
| SSY Group Limited | 1.98 Billion HKD | 99.137% |
| JBM (Healthcare) Limited | 163.87 Million HKD | 89.564% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | 94.048% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 99.942% |